Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/AIPortfolios by manojs. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated’s share was trading at $454.08 as of March 20th. VRTX’s trailing and forward P/E were 29.63 and 23.81 respectively according to Yahoo Finance.
robina-weermeijer–szKjHyPq28-unsplash
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. VRTX has attracted bullish investor attention following positive developments across its pipeline and strong financial positioning. The company’s outlook is underpinned by the Phase 3 interim success of povetacicept in IgA nephropathy, which demonstrated a 49.8% reduction in proteinuria, de-risking the asset and fueling a 6.58% stock rally on March 9, accompanied by analyst upgrades.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Vertex plans a rolling BLA submission by the end of March 2026, presenting a near-term regulatory catalyst with potential for accelerated approval. Beyond povetacicept, the company’s non-CF pipeline shows robust momentum, with Journavx prescriptions expected to more than triple in 2026 and Gernavix Phase 4 data imminent, highlighting significant future growth potential. Financially, Vertex remains solid, with Q4 revenue up 10% year-over-year and 2026 guidance indicating 8–9% top-line growth, while $12.3 billion in cash provides ample resources to fund ongoing R&D initiatives.
The broader biotech sector tailwinds, including easing Treasury yields at 4.13% and Fed funds at 3.64%, further support growth-oriented stocks like VRTX. Technically, the stock shows a neutral-to-positive setup, trading near key moving averages with an RSI of 51, while analyst price targets average $550, implying roughly 15% upside from the recent close of $479.98. Overall, Vertex combines strong near-term regulatory catalysts, expanding pipeline opportunities, robust financial health, and favorable sector dynamics, making it a compelling growth-focused investment with both upside potential and manageable risk.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, strong gene-editing pipeline, low dilution risk, and favorable biotech macro trends. CRSP’s stock price has appreciated by approximately 12.86% since our coverage. Manojs shares a similar view but emphasizes Vertex Pharmaceuticals Incorporated’s Phase 3 povetacicept success and near-term regulatory catalysts.
Vertex Pharmaceuticals Incorporated is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge fund portfolios held VRTX at the end of the fourth quarter which was 61 in the previous quarter. While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
